drugset / Trial / NCT02906696
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
Phase 2
Terminated
8 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure. Bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2016-10-28
- Primary completion
- 2019-08-08
- Completion
- 2019-08-08
Outcome
Outcome not reported
Stopped: “Terminated per PI's request due to competing priorities.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | 300 mg | Oral |
| Subject | Bosutinib | Small molecule | 400 mg | Oral |
| Subject | Bosutinib | Small molecule | 500 mg | Oral |
| Subject | Bosutinib | Small molecule | 600 mg | Oral |